Indian-origin man shot dead in Canada's Burnaby, was it a gang war? Details here
Babar Azam IN, Haris Rauf OUT: Pakistan announce 15-member squad for T20I World Cup 2026
'Dawn of a New Era': Tejashwi Yadav appointed as new RJD chief by father Lalu Prasad Yadav
PM Modi in Mann Ki Baat: Indian start-ups working across AI, space, semiconductors
Republic Day 2026: Is India celebrating the 77th or 78th Republic Day? Know everything here
IND vs NZ 3rd T20I: Will rain disrupt India vs New Zealand game in Guwahati?
BUSINESS
The drug falls in the anti-diabetes segment and the group's formulations manufacturing site at Baddi will be producing the drug for the US market, Cadila Healthcare said.
Drug firm Zydus Cadila has received a final nod from the US health regulator to sell anti-diabetics Glyburide and Metformin Hcl tablets in the American market.
"Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Glyburide and Metformin Hcl tablets USP in strengths of 1.25/250, 2.5/500 and 5/500 mg," Cadila Healthcare said in a BSE filing.
The drug falls in the anti-diabetes segment and the group's formulations manufacturing site at Baddi will be producing the drug for the US market, it added.
"The group now has 103 approvals and has so far filed over 280 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04," Cadila Healthcare said.
At 1514, the shares of Cadila Healthcare were trading up 3.27% or Rs 10.30 at Rs 325.10 per scrip on the BSE.